Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | LDLR | P01130 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609240 | 0.89 | CNR2 (0.44) | CNR1CNR2CREBBPBRD4 | |
| SCHEMBL3970983 | 0.79 | PTGER4 (0.50) | RXFP1ALDH1A1ALDH3A1KDM4EHPGD | |
| SCHEMBL1608768 | 0.79 | CREBBP (0.44) | CNR1CNR2CREBBPKDM4EBRD4 | |
| SCHEMBL14116535 | 0.76 | HTT (0.45) | RXFP1ALDH1A1ALDH3A1KDM4EHPGD | |
| SCHEMBL3966385 | 0.75 | HTT (0.60) | ALDH1A1ALDH3A1KDM4EHPGD | |
| SCHEMBL5146048 | 0.75 | DHODH (0.54) | ALDH1A1KDM4EHPGDEPHX1DHODH | |
| SCHEMBL3975552 | 0.74 | PTGER4 (0.47) | RXFP1ALDH1A1ALDH3A1KDM4EEPHX1 | |
| SCHEMBL6819536 | 0.73 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDEPHX1 | |
| SCHEMBL5881733 | 0.72 | PTGER4 (0.56) | ALDH1A1KDM4EMAPK14 | |
| SCHEMBL6815244 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | CYP3A4, CYP2C19, H1-3 | CNR1 689/4885CNR2 691/4885RXFP1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.